Abstract: The present disclosure provides a signal transmission/reception method, user equipment, and network equipment, the method including: determining, by a user equipment, an available random access occasion and a timing advance (TA) value; performing listen before talk (LBT) before a TA of the first available random access occasion; transmitting, if the LBT is successful, the random access preamble on the random access occasion.

Abstract: A Streptococcus suis (S. suis) vaccine is provided. For the S. suis vaccine, an antigen is a protein with an amino acid sequence shown in SEQ ID NO: 2. A preparation method of the S. suis vaccine is provided, including the following steps: mixing a white oil and aluminum stearate to obtain a white oil adjuvant; adding poly sorbate 80 to an aqueous solution of the protein with the amino acid sequence shown in SEQ ID NO: 2, and thoroughly mixing to obtain an antigen solution; and mixing the antigen solution with the white oil adjuvant according to a volume ratio of (0.5-1.5):2, and emulsifying to obtain the S. suis vaccine. An animal immunized with the S. suis vaccine of the present disclosure can effectively resist the attack of S. suis serotype 2, 3, and 31, with a vaccine protection rate as high as 100%.

Abstract: Embodiments of the present disclosure relate to automated validation of medical data. Some embodiments of the present disclosure provide a method for medical data validation. The method comprises obtaining target medical data generated in a medical test and obtaining a machine learning model for validating medical data. The machine learning model represents an association between the medical data and validation results, the validation results indicating information about predetermined actions to be performed on the medical data. The method further comprises determining a target validation result for the target medical data by applying the target medical data to the machine learning model, the target validation result indicating information about a target action selected from the predetermined actions to be performed on the target medical data. Through the solution, it is possible to achieve automated medical data validation with high accuracy and efficiency as well as reduced manual efforts.

Abstract: The present disclosure relates to a pre-5th-Generation (5G) or 5G communication system to be provided for supporting higher data rates Beyond 4th-Generation (4G) communication system such as Long Term Evolution (LTE). The present application discloses a power headroom report (PHR) method and apparatus. A user equipment (UE) determines a PHR reporting manner according to the structure of an uplink subframe in an active serving cell, calculates PHR according to the reporting manner, and sends the PHR to a base station. According to the present disclosure, a UE proactively determines the PHR reporting manner, calculates PHR and report the PHR, thus implements PHR reporting process at the UE.

Abstract: Methods and systems for correcting an error of a GPS signal are provided. The method includes receiving a request for positioning service from a computing device at a location; estimating a Total Electron Content (vTEC) value associated with the location of the object based at least in part on a plurality of vTEC values of a plurality of ground stations equipped with a plurality of GPS receivers, the vTEC value being estimated based on an estimator that is trained using a filter-reweight-retrain robust algorithm; and sending information of the estimated vTEC value to the computing device to allow the computing device to correct an error of a GPS signal received by the computing device, the error of the GPS signal being associated with an ionospheric delay.

Abstract: A preparation method for a low oxygen content semiconductor core composite material optical fibre preform comprise: (1) in a nitrogen gas atmosphere glovebox, tightly packing semiconductor core raw material powder into a central hole of a cladding glass tube which is sealed at one end; and (2) performing vacuum pumping on the cladding glass tube packed with the semiconductor core raw material powder, and simultaneously sealing another end of the hot-drawn glass tube to vacuum sealing the semiconductor core raw material powder within the cladding glass tube, so as to obtain the low oxygen content semiconductor core composite material optical fibre preform. The method solves problems in the traditional optical fibre preform preparation methods such as poor packing tightness, high oxygen content in drawn fibre cores, and poor transmission performance in prepared optical fibres.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: A polymer with alternating phenylene silicon and siloxane structure and a method of producing a precursor of the same are introduced to develop an autonomous synthesis process for para-phenylene disilanol monomer compounds and design a technique of purifying the polymer with alternating phenylene silicon and siloxane structure easily, so as to enable mass production of the polymer with alternating phenylene silicon and siloxane structure.

Abstract: A polymer with alternating phenylene silicon and siloxane structure and a method of producing a precursor of the same are introduced to develop an autonomous synthesis process for para-phenylene disilanol monomer compounds and design a technique of purifying the polymer with alternating phenylene silicon and siloxane structure easily, so as to enable mass production of the polymer with alternating phenylene silicon and siloxane structure.

Abstract: Methods and systems for distance metric learning include generating two random projection matrices of a dataset from a d-dimensional space into an m-dimensional sub-space, where m is smaller than d. An optimization problem is solved in the m-dimensional subspace to learn a distance metric based on the random projection matrices. The distance metric is recovered in the d-dimensional space.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: Methods and systems for distance metric learning include generating two random projection matrices of a dataset from a d-dimensional space into an m-dimensional sub-space, where m is smaller than d. An optimization problem is solved in the m-dimensional subspace to learn a distance metric based on the random projection matrices. The distance metric is recovered in the d-dimensional space.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.

Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.